Wikipedia

Bharat Biotech

17°39′55″N78°36′17″E/ 17.6652°N 78.6047°E/17.6652; 78.6047

Bharat Biotech International Limited
Company typePrivate Limited Company
IndustryBiotechnology
Founded1996;29 years ago(1996)
FounderDr.Krishna Ella
HeadquartersGenome Valley,Turakapally,Hyderabad,India
Area served
Worldwide
Key people
Dr.Krishna Ella
(Chairman&MD)
Products
RevenueIncrease₹8,148 crore(US$940 million) (FY22)[3]
Increase₹2,895 crore(US$330 million) (FY22)[3]
SubsidiariesChiron Behring Vaccines[4]
Websitewww.bharatbiotech

Bharat Biotech International Limited (BBIL)is an Indian multinationalbiotechnologycompany based inHyderabad,which is engaged indrug discovery,drug development,and the manufacture ofvaccines,biotherapeutics,pharmaceuticalsand healthcare products.[5]

Overview

edit

Bharat Biotech has its manufacturing facility situated atGenome Valley,Hyderabad,India.[5]As of July 2020, the company has over 700 employees[6]and has a presence worldwide.[5]

The company has been responsible for developing an eco-friendly recombinant[7]and a naturally attenuated strain derived Rotavirus vaccine called ROTAVAC.[8][9]They were one of the first to develop vaccines for viral diseases likeChikungunya[10][11]andZika.[12][13]The company also produces vaccines forJapanese Encephalitis.[14]Bharat Biotech hasbiosafety level 3(BSL3) laboratories.[15]

COVID-19 vaccine development

edit
See also:Covaxin,BBV154,andCOVID-19 vaccine

In April 2020, the company announced that they have partnered with US-based company FluGen andUniversity of Wisconsin-Madisonto develop a COVID-19 vaccine.[16][17]

A 5ml vial of Covaxin

In May 2020, Indian Council of Medical Research's (ICMR's)National Institute of Virologyapproved and provided the virus strains for developing a fully indigenousCOVID-19vaccine.[18][19]On June 29, 2020, the company got permission to conduct Phase 1 and Phase 2clinical trials in Indiafor a developmentalCOVID-19vaccine namedCovaxin,from the Drugs Controller General of India (DCGI),Government of India.[20][21][22][23]The Central Drugs Laboratory (CDL) at Kasauli in Himachal Pradesh has been engaged in testing experimental batches of Bharat Biotech's COVID-19 vaccine Covaxin on a priority basis.[24]A total of 12 sites were selected by theIndian Council for Medical Researchfor Phase I and II randomised, double-blind and placebo-controlled clinical trials of vaccine candidate.[25][26]

In September 2020, the company announced that it was going to manufacture the novelchimp-adenovirus,a single doseintranasalvaccine (codenamedBBV154) forCOVID-19being developed in collaboration with the American company Precision virologics[27]andWashington University School of MedicineinSt. Louis, Missouri.It is currently undergoing clinical trials.[28][29]On October 12 2021, Bharat Biotech's Covaxin got approved for usage on children between 2 and 18 years of age.[30]

Attempted data theft

edit

In March 2021,Reutersreported that Chinese state-backed cyber-espionage groupRed Apollotargeted Bharat Biotech's intellectual property forexfiltration.[31]

See also

edit

References

edit
  1. ^"WHO prequalifies new rotavirus vaccine".WHO.Archived fromthe originalon 17 July 2020.Retrieved2 July2020.
  2. ^"WHO recommends use of first typhoid conjugate vaccine".WHO.Archived fromthe originalon 7 September 2018.Retrieved2 July2020.
  3. ^ab"Bharat Biotech International Limited: Ratings reaffirmed".ICRA.Retrieved16 April2024.
  4. ^"Bharat Biotech buys Chiron Behring Vaccines from GSK".The Hindu BusinessLine.15 February 2019.Archivedfrom the original on 31 August 2020.Retrieved1 July2020.
  5. ^abc"Bharat Biotech International Ltd".bloomberg.Archivedfrom the original on 16 November 2020.Retrieved3 July2020.
  6. ^"Leading Biotech Vaccine Manufacturers in India - Bharat Biotech".bharatbiotech.Archivedfrom the original on 5 July 2020.Retrieved30 June2020.
  7. ^"Process for the preparation and purification of recombinant proteins".patents.google.US patent No US8956812B2. 23 August 2004.Archivedfrom the original on 9 May 2021.Retrieved30 June2020.
  8. ^Bhandari, Nita; Rongsen-Chandola, Temsunaro; Bavdekar, Ashish; John, Jacob; Antony, Kalpana; Taneja, Sunita; Goyal, Nidhi; Kawade, Anand; Kang, Gagandeep; Rathore, Sudeep Singh; Juvekar, Sanjay; Muliyil, Jayaprakash; Arya, Alok; Shaikh, Hanif; Abraham, Vinod; Vrati, Sudhanshu; Proschan, Michael; Kohberger, Robert; Thiry, Georges; Glass, Roger; Greenberg, Harry B; Curlin, George; Mohan, Krishna; Harshavardhan, G V J A; Prasad, Sai; Rao, T S; Boslego, John; Bhan, Maharaj Kishan (June 2014)."Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial".The Lancet.383(9935):2136–2143.doi:10.1016/S0140-6736(13)62630-6.PMC4532697.PMID24629994.
  9. ^Kang, G (October 2006)."Rotavirus vaccines".Indian Journal of Medical Microbiology.24(4):252–7.doi:10.1016/S0255-0857(21)02284-2.PMC2481304.PMID17185842.
  10. ^"Bharat Biotech's Zika, Chikungunya vaccines to enter Phase II trials; focus now on private label market".Moneycontrol.Archivedfrom the original on 30 June 2020.Retrieved30 June2020.
  11. ^"CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원".CEPI, 치쿤구니아 백신 개발 위해 국제백신연구소-바라트 바이오텍 컨소시엄에 최대 1410만달러 지원 - 뉴스와이어(in Korean). 3 June 2020.
  12. ^"Bharat Biotech gets breakthrough in developing Zika vaccine".The Economic Times.4 February 2016.Archivedfrom the original on 9 May 2021.Retrieved30 June2020.
  13. ^"CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI – IVI".ivi.int.International Vaccine Institute. 3 June 2020.Archivedfrom the original on 24 September 2020.Retrieved30 June2020.
  14. ^Singh, Anit; Mitra, Monjori; Sampath, Gadey; Venugopal, P.; Rao, J. Venkateswara; Krishnamurthy, B.; Gupta, Mukesh Kumar; Sri Krishna, S.; Sudhakar, B.; Rao, N. Bhuvaneswara; Kaushik, Yashpal; Gopinathan, K.; Hegde, Nagendra R.; Gore, Milind M.; Krishna Mohan, V.; Ella, Krishna M. (1 September 2015)."A Japanese Encephalitis Vaccine From India Induces Durable and Cross-protective Immunity Against Temporally and Spatially Wide-ranging Global Field Strains".Journal of Infectious Diseases.212(5):715–725.doi:10.1093/infdis/jiv023.PMID25601942.
  15. ^"Slow off the starting blocks for Bharat Biotech's Covaxin mass production".The New Indian Express.17 May 2021.Retrieved4 June2021.
  16. ^"UW-Madison, Flugen, Bharat Biotech to develop coroflu, a coronavirus vaccine".Global Health Institute.Archivedfrom the original on 10 February 2021.Retrieved30 June2020.
  17. ^"Bharat Biotech ties up with US varsity for Covid vaccine".Hindustan Times.20 May 2020.Archivedfrom the original on 3 May 2021.Retrieved30 June2020.
  18. ^"ICMR teams up with Bharat Biotech to develop Covid-19 vaccine".Livemint.9 May 2020.Archivedfrom the original on 3 May 2021.Retrieved30 June2020.
  19. ^Chakrabarti, Angana (10 May 2020)."India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech".ThePrint.Archivedfrom the original on 3 May 2021.Retrieved30 June2020.
  20. ^"India's First COVID-19 Vaccine Candidate Approved for Human Trials".The New York Times.29 June 2020.Archivedfrom the original on 2 July 2020.Retrieved30 June2020.
  21. ^"Human trial of India coronavirus vaccine announced".BBC News.30 June 2020.Archivedfrom the original on 3 May 2021.Retrieved30 June2020.
  22. ^"Bharat Biotech's Covid vaccine 1st in India to get approval for human trials".The Indian Express.30 June 2020.Archivedfrom the original on 3 May 2021.Retrieved30 June2020.
  23. ^"Covaxin: India's first COVID19 vaccine candidate from Bharat Biotech to begin human trials; check details".The Financial Express.30 June 2020.Archivedfrom the original on 3 May 2021.Retrieved30 June2020.
  24. ^"Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins".Moneycontrol.Archivedfrom the original on 10 July 2020.Retrieved10 July2020.
  25. ^"Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS".DD News.Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020.Archivedfrom the original on 24 January 2021.Retrieved7 August2020.
  26. ^"Delhi: 30-year-old is first to get dose of trial drug Covaxin".The Indian Express.25 July 2020.Archivedfrom the original on 16 March 2021.Retrieved7 August2020.
  27. ^"COVID-19 | Office of Technology Management/Tech Transfer | Washington University in St. Louis".
  28. ^"Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine".The Indian Express.23 September 2020.Archivedfrom the original on 3 May 2021.Retrieved23 September2020.
  29. ^"Bharat Biotech Partners With US University For Covid Intranasal Vaccine".NDTV.Archivedfrom the original on 3 May 2021.Retrieved23 September2020.
  30. ^"COVID-19: Covaxin Vaccine Approved For Children Between 2 to 18".The Live Mirror.12 October 2021.Retrieved12 October2021.
  31. ^Das, Krishna N. (1 March 2021)."Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm".Reuters.Archivedfrom the original on 3 May 2021.Retrieved1 March2021.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bharat_Biotech&oldid=1247051741"